We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+1.5%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.24B
AUM Growth
-$1.73B
Cap. Flow
-$1.75B
Cap. Flow %
-141.12%
Top 10 Hldgs %
32.38%
Holding
322
New
31
Increased
40
Reduced
64
Closed
112

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$36.4M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$12.7M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$11.6M
4
CGEM icon
Cullinan Oncology
CGEM
+$9.06M
5
ALEC icon
Alector
ALEC
+$7.87M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$24M
2
CRIS icon
Curis
CRIS
+$13.8M
3
NBP
NovaBridge Biosciences American Depositary Shares
NBP
+$13.5M
4
PRTA icon
Prothena Corp
PRTA
+$11M
5
TVRD
Tvardi Therapeutics
TVRD
+$9.32M

Sector Composition

Rank Sector Weight
1 Healthcare 43.58%
2 Technology 0.24%
3 Consumer Staples 0.11%
4 Financials 0.06%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
276
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$784B
– –
-550,000
Closed -$218M
SRPT icon
277
Sarepta Therapeutics
SRPT
$1.64B
– –
-134
Closed -$10.2K
SRPT icon
278
PUT
Sarepta Therapeutics
SRPT
$1.64B
– –
-455,900
Closed -$34M
SRRK icon
279
CALL
Scholar Rock
SRRK
$5.87B
– –
-28,300
Closed -$1.43M
SRRK icon
280
Scholar Rock
SRRK
$5.87B
– –
-67,059
Closed -$3.4M
STRO icon
281
CALL
Sutro Biopharma
STRO
$411M
– –
-20,000
Closed -$4.55M
TDOC icon
282
PUT
Teladoc Health
TDOC
$1.2B
– –
-6,500
Closed -$1.18M
TLT icon
283
CALL
iShares 20+ Year Treasury Bond ETF
TLT
$42.4B
– –
-400,000
Closed -$54.2M
TLT icon
284
PUT
iShares 20+ Year Treasury Bond ETF
TLT
$42.4B
– –
-300,000
Closed -$40.6M
TNGX icon
285
Tango Therapeutics
TNGX
$4.49B
– –
-300,250
Closed -$3.34M
TWST icon
286
PUT
Twist Bioscience
TWST
$5.69B
– –
-120,000
Closed -$14.9M
TXG icon
287
PUT
10x Genomics
TXG
$6.28B
– –
-70,000
Closed -$12.7M
UTHR icon
288
CALL
United Therapeutics
UTHR
$26.2B
– –
-105,000
Closed -$17.6M
VIR icon
289
PUT
Vir Biotechnology
VIR
$1.5B
– –
-250,000
Closed -$12.8M
VRTX icon
290
PUT
Vertex Pharmaceuticals
VRTX
$122B
– –
-200,000
Closed -$43M
WVE icon
291
CALL
Wave Life Sciences
WVE
$1.13B
– –
-250,000
Closed -$1.4M
XBI icon
292
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.3B
– –
-350,000
Closed -$47.5M
XBI icon
293
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
– –
-950,000
Closed -$129M
XLF icon
294
CALL
State Street Financial Select Sector SPDR ETF
XLF
$56.8B
– –
-1,109,400
Closed -$37.8M
XLI icon
295
CALL
State Street Industrial Select Sector SPDR ETF
XLI
$32.5B
– –
-500,000
Closed -$49.2M
XLU icon
296
CALL
State Street Utilities Select Sector SPDR ETF
XLU
$23B
– –
-400,000
Closed -$12.8M
ZLAB icon
297
Zai Lab
ZLAB
$2.06B
– –
-17,000
Closed -$2.73M
ONC
298
CALL
BeOne Medicines Ltd
ONC
$33.4B
– –
-10,500
Closed -$3.65M
ONC
299
PUT
BeOne Medicines Ltd
ONC
$33.4B
– –
-160,500
Closed -$55.9M
KLRS
300
CALL
Kalaris Therapeutics
KLRS
$82.8M
– –
-8,696
Closed -$4.68M
9 10 11
12
13

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Ikarian Capital held 322 positions worth $1.24B, down 58% from $2.97B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Ikarian Capital withdrew a net $1.75B in Q2 2021, closing 112 positions and reducing 64 holdings. Its most notable exit was Curis, an estimated $13.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 22% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Ikarian Capital opened a new position in ChemoCentryx, Inc. worth $6.31M.

  • Ikarian Capital's largest Q2 2021 buy was ChemoCentryx, Inc.: 471,376 shares worth $6.31M.
  • Ikarian Capital added most to Biogen in Q2 2021, an estimated $36.4M increase.
  • Ikarian Capital's biggest Q2 2021 reduction was Eli Lilly, cutting an estimated $24M.
  • Ikarian Capital fully exited Curis in Q2 2021, selling an estimated $13.8M.
  • Ikarian Capital's ten largest holdings make up 32% of its $1.24B portfolio in Q2 2021.
  • Ikarian Capital opened 31 new positions and closed 112 in Q2 2021.
  • Ikarian Capital's portfolio value fell 58% quarter-over-quarter to $1.24B.

Based on Ikarian Capital's 13F filing for Q2 2021, filed 16 Aug 2021.